Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Immix Biopharma Inc (IMMX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/16/2025: IMMX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -32.73% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 48.51M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 45862 | Beta 0.29 | 52 Weeks Range 1.26 - 2.71 | Updated Date 04/25/2025 |
52 Weeks Range 1.26 - 2.71 | Updated Date 04/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.76 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -66.11% | Return on Equity (TTM) -147.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 31906505 | Price to Sales(TTM) - |
Enterprise Value 31906505 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.37 | Shares Outstanding 27722100 | Shares Floating 17986658 |
Shares Outstanding 27722100 | Shares Floating 17986658 | ||
Percent Insiders 39.79 | Percent Institutions 12.04 |
Analyst Ratings
Rating 4 | Target Price 7 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Immix Biopharma Inc
Company Overview
History and Background
Immix Biopharma, Inc. is a biopharmaceutical company focused on developing novel therapies for cancer and other life-threatening diseases. It was founded with a focus on Tissue-Specific Therapeutics (TSTx) platform. Details on specific founding year and early milestones are limited in publicly available information.
Core Business Areas
- TSTx Platform: Development of Tissue-Specific Therapeutics (TSTx) platform targeting cancer cells while sparing healthy tissue.
- Drug Development: Focus on developing drug candidates for various cancer indications, including relapsed/refractory cancers.
Leadership and Structure
Details on the specific leadership team and organizational structure are not widely available but can be found in their SEC filings and investor relations materials.
Top Products and Market Share
Key Offerings
- IMX-110: IMX-110 is Immix Biopharma's lead drug candidate, focusing on soft tissue sarcoma. Specific market share data or revenue is unavailable. Competitors include companies developing therapies for soft tissue sarcoma, such as Eli Lilly (LLY) with Olaratumab.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. The oncology segment is particularly competitive.
Positioning
Immix Biopharma is positioned as a company developing targeted therapies using its TSTx platform, aiming to address unmet needs in cancer treatment.
Total Addressable Market (TAM)
The TAM for cancer therapeutics is substantial, estimated in the hundreds of billions of dollars globally. Immix Biopharma is aiming to capture a portion of this market with its targeted therapies, specifically focusing on unmet needs in relapsed/refractory cancers.
Upturn SWOT Analysis
Strengths
- Proprietary TSTx platform
- Targeted therapy approach
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Early-stage development pipeline
- Reliance on a single technology platform
Opportunities
- Partnerships and collaborations
- Expansion to new indications
- Positive clinical trial results
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- LLY
- MRK
- BMY
Competitive Landscape
Immix Biopharma faces intense competition from larger, well-established pharmaceutical companies. Its TSTx platform could provide a competitive advantage if proven effective.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited in the provided context.
Future Projections: Future growth projections are dependent on the success of clinical trials and regulatory approvals. Analyst estimates are unavailable.
Recent Initiatives: Recent initiatives likely include clinical trial advancements and potential partnerships.
Summary
Immix Biopharma is an early-stage biopharmaceutical company focused on developing targeted cancer therapies. Its TSTx platform is a potential strength, but it faces significant challenges including limited resources and competition from larger companies. Success hinges on positive clinical trial results and securing partnerships. Investment in Research and Development is key for growth.
Similar Companies
CRVS
Corvus Pharmaceuticals Inc
CRVS
Corvus Pharmaceuticals Inc
XOMA
XOMA Corp
XOMA
XOMA Corp
ZYME
Zymeworks Inc. Common Stock
ZYME
Zymeworks Inc. Common Stock
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immix Biopharma Inc
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2021-12-16 | Co-Founder, CEO & Chairman Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 18 | Website https://www.immixbio.com |
Full time employees 18 | Website https://www.immixbio.com | ||
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.